Dernière mise à jour : 11 avril 2013
Détails
FichiersGeneric Name:
Everolimus
État du projet:
Terminé
Domaine thérapeutique:
Advanced Breast Cancer
Fabricant:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Afinitor
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0014-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
2.5 mg, 5mg and 10 mg
Tumour Type:
Breast
Indications:
Advanced Breast Cancer
Funding Request:
For treatment of post menopausal women with hormone receptor-positive advanced breast cancer in combination with exemestane, after progression or recurrence (failure) on NSAI therapy.
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 11 avril 2013